New treatments for atopic dermatitis

Immunology and Allergy Clinics of North America

Volumn 22, Issue 1, 2002, Pages 141-152

  Schneider, Lynda C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOMODULATING AGENT; INTERLEUKIN 4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PROBIOTIC AGENT; TACROLIMUS;

ASTHMA; ATOPIC DERMATITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOOD ALLERGY; HUMAN; IMMUNOMODULATION; OINTMENT; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0036168175     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8561(03)00074-2     Document Type: Review

References (52)

1. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome
2. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis
3. Cyclosporine in severe childhood atopic dermatitis: A multicenter study
4. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children
5. Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels
6. Treatment of children with atopic dermatitis with 1% SDZ ASM 981 cream
7. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis
8. Interferon-γ therapy reduces blood leukocyte levels in patients with atopic dermatitis: Correlation with clinical improvement
9. Results of a phase III study of recombinant interferon-γ 1b in patients with moderate to severe atopic dermatitis
10. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
11. Importance of intestinal colonisation in the maturation of humoral immunity in early infancy: A prospective follow up study of healthy infants aged 0-6 months
12. Differential in situ gene expression in acute vs chronic atopic dermatitis
13. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. Part I: Efficacy
14. Recombinant interferon-γ therapy for atopic dermatitis
15. First experience of topical SDZ ASM 981 in children with atopic dermatitis
16. Tacrolimus (FK506): New treatment approach in superantigen-associated diseases like atopic dermatitis
17. Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cells in severe atopic dermatitis after intravenous immunoglobulin therapy
18. Probiotics in the management of atopic eczema
19. Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis
20. The treatment of atopic dermatitis with adjunctive high-dose immunoglobulin: A report of three patients and review of the literature
21. Probiotics in primary prevention of atopic disease
22. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children
23. Atopic dermatitis: New insights and opportunities for therapeutic intervention
24. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis
25. Probiotics: A novel approach in the management of food allergy
26. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma
27. ASM 981 and clobetasol propionate show similar inhibition of the DNFB-induced allergic contact dermatitis in Gottingen minipigs
28. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology
29. Intravenous immunoglobulin therapy for infants with severe atopic dermatitis and hypogammaglobulinemia
30. Treatment of atopic eczema with oral mycophenolate mofetil
31. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis
32. Pilot study of IFN-gamma-induced specific hyposensitization for house dust mites in atopic dermatitis: IFN-gamma-induced immune deviation as a new therapeutic concept for atopic dermatitis
33. Use of nonsteroidal topical immunonmodulators for the treatment of atopic dermatitis in the pediatric population
34. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients
35. Human epidermal Langerhans' cells ate targets for the immunosuppressive macrolide tacrolimus (FK506)
36. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial
37. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis
38. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions
39. A short-term trial of tacrolimus ointment for atopic dermatitis
40. Effect of intravenous immunoglobulin on steroid consumption in patients with asthma: A double-blind, placebo-controlled, randomized trial
41. Staphylococcal septicaemia complicating treatment of atopic dermatitis with mycophenolate
42. Long-term therapy with recombinant interferon-gamma for atopic dermatitis
43. FK506 inhibition of histamine release and cytokine production by mast cells and basophils
44. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II. Safety
45. Roles of Th1 and Th2 cytokines in a murine model of allergic dermatitis
46. Long term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels
47. Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG-derived enzymes
48. Effectiveness of the ascomycin macrolactam SDZ ASM981 in the topical treatment of atopic dermatitis
49. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome
50. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis
51. A pilot study examining the role of zileutton in atopic dermatitis
52. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis